The CSF concentrations of pralsetinib (Gavreto®) and osimertinib were investigated in an adult patient with an EGFR-mutant NSCLC with acquired RET fusions and meningeal metastasis after four months of co-treatment with pralsetinib and osimertinib. Here, RET is linked to non-small cell lung carcinoma.